INFINIUM PHARMACHEM LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.1 INR | -2.79% |
|
+1.03% | -5.91% |
| Sales 2022 | 747M 8.96M | Sales 2023 | 1.14B 13.69M | Capitalization | 3.16B 37.94M |
|---|---|---|---|---|---|
| Net income 2022 | 55M 659K | Net income 2023 | 94M 1.13M | EV / Sales 2022 * | - |
| Net cash position 2022 * | - 0 | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 130 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.79% | ||
| 1 week | +1.03% | ||
| Current month | +1.54% | ||
| 1 month | +1.05% | ||
| 3 months | -4.70% | ||
| 6 months | -6.03% | ||
| Current year | -5.91% |
1 week
209.00
229.00
1 month
209.00264.00
Current year
200.00273.00
1 year
130.00315.70
3 years
70.75315.70
5 years
70.75315.70
10 years
70.75315.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 44 | 21/03/21 | |
Nilesh Patel
DFI | Director of Finance/CFO | - | 20/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 45 | 14/22/14 | |
| Chief Executive Officer | 44 | 21/03/21 | |
| Director/Board Member | 48 | 21/03/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 221.1 | -2.79% | 7 500 |
| 25/24/25 | 227.4 | +1.29% | 19,500 |
| 24/24/24 | 224.6 | +4.56% | 53,500 |
| 21/24/21 | 214.8 | -0.12% | 32,500 |
| 20/24/20 | 215 | -2.38% | 28,000 |
Delayed Quote NSE India S.E., June 26, 2024 at 10:18 am IST
More quotes
Infinium Pharmachem Limited (Infinium) is an India-based company. The Company is involved in the development, manufacture, and export of a spectrum of the Iodine Derivatives that are used in pharmaceutical, chemical, biotech and allied industries across the globe. The Company's portfolio includes approximately 200+ Iodine Derivatives and seven+ APIs. It manufactures and supplies a range of Iodine based APIs, but on Order to Made basis only. It offers bulk actives, intermediates and services for custom synthesis. It also provides contract Research and manufacturing Services to the pharmaceutical and biotech companies for their diverse requirements of Iodine based APIs and intermediates to reduce their research time and project cost. It manufactures iodine derivatives for the various industries, including pharmaceutical, chemical, nutraceutical, cosmetics, sanitation, agrochemical, electronics, Nylon production and other industries for their range of industrial applications.
Sector
Diversified Chemicals
Calendar
06/07/2024
- Extraordinary Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -5.91% | 37.94M | |
| +4.92% | 76.21B | |
| -4.86% | 44.33B | |
| +4.59% | 33.64B | |
| +16.79% | 19.13B | |
| +9.05% | 11.52B | |
| -22.13% | 10.01B | |
| -5.80% | 10B | |
| -1.64% | 8.96B | |
| -3.47% | 8.51B |
- Stock Market
- Equities
- INFINIUM Stock
